elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Mass cytometry
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Mass cytometry
RIS
0.001
(Research Intensity Score)
Papers
124
Top papers
B cells and tertiary lymphoid structures promote immunotherapy response
2020 · 2815 citations
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
2023 · 145 citations
Opening the doors of precision medicine: novel tools to assess intestinal barrier in inflammatory bowel disease and colitis-associated neoplasia
2024 · 99 citations
Multispectral fluorine-19 MRI enables longitudinal and noninvasive monitoring of tumor-associated macrophages
2022 · 98 citations
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers
2025 · 24 citations
Newest papers
Mass cytometry as a tool to evaluate chronic inflammatory airway diseases
2026
H 2 S-Activable BiFeO 3– x Nanocatalysts for Ferroptosis-Driven Cancer Immunotherapy
2026 · 1 citations
Immune dysregulation and exhaustion in EBV- associated hemophagocytic lymphohistiocytosis: insights from single-cell transcriptomics and TCR repertoire analysis
2026
Differential Correlation Across Subpopulations of Single Cells in Subtypes of Acute Myeloid Leukemia
2026
Editorial: Multiomics advances: bridging gaps in understanding intricate biological systems
2026
A sample from the 100 top papers behind Mass cytometry.
Create a free account to browse them all →
Mass cytometry's history
Research intensity over time
Explore Mass cytometry's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Mass cytometry's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link